Clinical Trial Update: A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial of CP-945,598 for obesity in overweight type 2 diabetic patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-945,598 (CP-945,598)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 3 | Status: TERMINATED